Earth Day 2010 is also about Better Health and Quality of Life

Earth Day 2010 is not just about recycling or climate change - it's about health. Regardless of whether to subscribe to the notion of global warming, clean our planet by getting involved in Earth Day events can provide the impetus needed for our legislators to listen to the necessary changes that can have a positive impact on global health. This year, Earth Day is April 22 and the 40th anniversary of this event.
Impact of environmental pollution and respiratory diseases, heart disease and cancer is well documented. Unfriendly chemicals, which include BPA, toxins in cosmetics, and environmental pesticides that get into our food sources and the environment have a negative impact on global health that many prefer to ignore. Over time, the culmination of an environmental protection system in combination with a genetic predisposition to the disease takes effect on health and on a global scale. Earth Day 2010 offers an opportunity to participate in changing the status quo.
Especially important for human health is the impact of even low levels of contamination which was found to increase risk of asthma for children, lead to inflammation in blood vessels that can lead to heart disease and increases the risk of recurrent heart attack. Air pollution affects the unborn baby and may lead to lower IQ levels. This year, during Earth Day 2010, you can make a difference, together with other like-minded individuals, pure life may reduce healthcare costs, improve quality of life, and lead to better health.
Harmful particulates into the environment was found in the 2009 study of gene damage in just three days, in studies designed to measure the risk of lung cancer in foundry workers. Earth Day 2010 began to rally to be held in Washington to urge lawmakers to take climate change and clean energy legislation this year.
Earth Day 2010 is not only politics and personal opinions. We are talking about global health, and the impact of life to less toxic planet. Health concerns are real.There no longer a question that the environmental movement is necessary for the protection of individual and planetary health, as evidenced by a sharp increase in cases of asthma, allergies, cardiovascular disease, cancer and birth defects - all of which are associated with the interaction with genes and our environment, which also affects the level of pollution in our homes. Contamination has also been linked with heart disease risk, but little has been done while the cash flows for the production of drugs to reduce heart attack risk.
Join Earth Day 2010 Movement and make a statement about your individual right to a healthy planet, which, in turn, reduced the incidence wide range of diseases, leading to sustainable and healthier food options, and energy and help us all live longer and better quality lives. Earth Day 2010 is one way to participate and make a resounding statement that legislators know that you care about your health and well-being. We're all just sick of the status quo. Get involved in activities that can help improve health and quality of life to spend money to develop more faith medicines and medical visits.

Sequential R-CHOP, Ibritumomab Tiuxetan Regimen Produces Impressive Survival Rates

In an oral presentation at the 10th International Conference on Malignant Lymphoma in Lugano, Switzerland, Paul A. Hamlin, MD, Memorial Sloan-Kettering Cancer Center, presented the results of an investigator-sponsored trial of the investigational treatment consolidation rituximab-CHOP (R-CHOP) with 90Yttrium Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy in high risk elderly patients with previously untreated high-intermediate and high risk diffuse large B-cell lymphoma (DLBCL). Cell Therapeutics Zevalin markets in the United States.
In high-risk elderly patient population with significant comorbidities, sequential R-CHOP followed by radioimmunotherapy resulted in excellent complete response and overall and disease-free survival, concluded Hamlin. This approach is currently the focus of international research phase III.
"Improved disease-free survival in these patients is an important unmet need in the result of poor for patients who relapse of the disease, and who can not tolerate intensive salvage therapy and stem cell transplantation," said Jack W. Singer, MD, chief medical officer officer by CTI. "Survival data from this study are very encouraging compared to historical data and provide the rationale for the registration of a randomized trial aimed Zevalin consolidation in higher risk patients with DLBCL."
Results of the study
Historical studies served as the background of the presentation indicate that approximately 50 percent of elderly patients with high risk diffuse large B-cell lymphoma (DLBCL) relapse after treatment with R-CHOP. Treatment options for patients who are not eligible for autologous stem cell transplantation is limited. In this analysis of 63 patients enrolled in the study, 39 patients were treated with Zevalin. The median age was 75 years (range 62-86), Karnofsky performance status <80 percent to 59 percent of patients with secondary status by 70 percent; prognostic score high-intermediate/high in 53 per cent and 47 per cent of patients, respectively. Moderate or high impact comorbidity is present in 86 percent. It is the intention to treat population, progression-free (PFS) and overall survival (OS) at 59 percent and 65 percent, respectively, at 22 months. In 39 patients who received Zevalin, PFS and OS were 78 percent and 82 percent, respectively, at 26 months.
Responses improved in 11 patients who received Zevalin, with eight patients improved from unconfirmed (CRU) with confirmed complete response (CR) and three patients improved from partial response (PR) to CR / CRU. Side effects reported included the suppression of blood: 26 percent and 36 percent of grade 3 / 4 neutropenia, 15 percent of third degree of anemia, and 36 percent and 31 percent of grade 3 / 4 thrombocytopenia. Six patients had delayed recovery of blood for more than 12 weeks. One patient developed myelodysplasia and two patients died after Zevalin was given, one of the suspected brain haemorrhage, and one of congestive heart failure.